Cargando…

Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Detalles Bibliográficos
Autores principales:	Sanchez-Piedra, Carlos, Diaz-Torne, Cesar, Manero, Javier, Pego-Reigosa, José M, Rúa-Figueroa, Íñigo, Gonzalez-Gay, Miguel A, Gomez-Reino, Juan, Alvaro-Gracia, Jose M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307213/ https://www.ncbi.nlm.nih.gov/pubmed/32503857 http://dx.doi.org/10.1136/annrheumdis-2020-217948

Ejemplares similares

Comment on: Comorbidities (excluding lymphoma) in Sjögren’s syndrome. Reply
por: Pego-Reigosa, José M, et al.
Publicado: (2021)

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021)

Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort
por: Tejera Segura, Beatriz, et al.
Publicado: (2019)

Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
por: Rafael-Vidal, Carlos, et al.
Publicado: (2020)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
por: Vela, Paloma, et al.
Publicado: (2020)

Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort
por: Narváez, Javier, et al.
Publicado: (2018)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort
por: Altabás-González, Irene, et al.
Publicado: (2022)

Adipokines, Metabolic Syndrome and Rheumatic Diseases
por: Abella, Vanessa, et al.
Publicado: (2014)

Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies
por: Martínez-Ramos, Sara, et al.
Publicado: (2022)

Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases
por: Scotece, Morena, et al.
Publicado: (2011)

Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases
por: Scotece, Morena, et al.
Publicado: (2012)

Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study
por: Urruticoechea-Arana, Ana, et al.
Publicado: (2015)

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
por: Rafael-Vidal, Carlos, et al.
Publicado: (2021)

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
por: Michelena, Xabier, et al.
Publicado: (2020)

Epigenetics in rheumatic diseases
por: Gay, Steffen
Publicado: (2014)

Chemistry of Tetradentate [C,N : C,N] Iminophosphorane Palladacycles: Preparation, Reactivity and Theoretical Calculations
por: Munín‐Cruz, Paula, et al.
Publicado: (2020)

Towards the cell-instructive bactericidal substrate: exploring the combination of nanotopographical features and integrin selective synthetic ligands
por: Fraioli, Roberta, et al.
Publicado: (2017)

Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry
por: Fernández-Nebro, Antonio, et al.
Publicado: (2015)

Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases
por: Rivera, Javier, et al.
Publicado: (2022)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
por: Valero-Jaimes, Jesús A., et al.
Publicado: (2021)

Utilidad de los estudios serológicos en los centros de Atención Primaria para el diagnóstico precoz de la enfermedad de Lyme
por: Vázquez-López, María Esther, et al.
Publicado: (2018)

Autoimmune Rheumatic Diseases
por: Anaya, Juan-Manuel, et al.
Publicado: (2014)

Environmental factors modulated ancient mitochondrial DNA variability and the prevalence of rheumatic diseases in the Basque Country
por: Laza, I. M., et al.
Publicado: (2019)

Synthetic Biology Tools for Engineering Microbial Cells to Fight Superbugs
por: León-Buitimea, Angel, et al.
Publicado: (2022)

Future direction of pathogenesis and treatment for rheumatic disorders
por: Gay, Steffen
Publicado: (2012)

Features of heritable disorders of connective tissue in children with acute rheumatic fever and rheumatic heart disease
por: Boyarchuk, Oksana
Publicado: (2020)

Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner
por: Carvalheiro, Tiago, et al.
Publicado: (2020)

Correction: CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis
por: Cordero, Oscar J., et al.
Publicado: (2015)

Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure
por: Rúa-Figueroa, Iñigo, et al.
Publicado: (2022)

Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables
por: Silva-Díaz, Maite, et al.
Publicado: (2021)

What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts
por: Mucke, Johanna, et al.
Publicado: (2021)

Features of rheumatic fever in adult patients in modern Kyrgyzstan
por: Omurzakova, Nazgul A, et al.
Publicado: (2012)

Distinctive CD26 Expression on CD4 T-Cell Subsets
por: Cordero, Oscar J., et al.
Publicado: (2021)

Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus
por: Sánchez-Pérez, Hiurma, et al.
Publicado: (2020)

Current landscape and future directions of synthetic biology in South America
por: Gomez-Hinostroza, E. Sebastian, et al.
Publicado: (2023)

Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
por: Mena-Vázquez, Natalia, et al.
Publicado: (2020)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
por: Sánchez-Piedra, Carlos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cjo05kh0oc22ajeok0i72vt8ch